Back to News
Market Impact: 0.15
Moderna Announces Late-Breaking Data to be Presented at ESMO Congress 2026
Source: Newswire
Healthcare & BiotechCorporate Guidance & Outlook
Moderna said Phase 3 data for intismeran autogene in adjuvant treatment of resected stage IIB-IV melanoma will be presented at a Presidential Symposium. The company will host a webcast investor event on October 24 at 7:00 PM CEST (1:00 PM EDT), but disclosed no efficacy, safety, or financial data.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
0.10
Ticker Sentiment
MRNA0.20
More News
- Moderna’s Bob Langer and AI pioneer Yann LeCun join board of Cellular Intelligence, bringing AI into medicine via a Parkinson’s drug
- Perpetual underdog AMD nips at Nvidia's heels as it joins the $1T club
- GRAIL Stock Bounces Back Above $100: Can Galleri Sail Through Its FDA Panel Review?
- Nvidia's Forecast Assumes No Data Center Chip Sales to China. The Sept. 24 U.S.-China Summit Could Change That.
- Eli Lilly CEO tells CNBC one-third of new GLP-1 pill patients are taking Foundayo, as drugmaker ramps up production
- Ra Capital Management sells $21.8m in Sionna Therapeutics shares
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- Reading Conviction in the Tape: What Level 3 Order Book Data Really Tells Discretionary PMs
- AI Tools for CFA Charterholders: An Evidence Standard